ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

MRI Contrast Reaction Management: Documentation & Protocol Guide Released

ContrastConnect's new documentation and protocol guide for MRI contrast reaction management incorporates 2025 ACR-AAAAI consensus recommendations that shift away from routine premedication for mild reactions and prioritize accurate EHR documentation of specific inciting agents.

-- ContrastConnect has released a Documentation & Protocol Guide addressing the management of hypersensitivity reactions to MRI contrast media, reflecting a significant shift in clinical practice.

More information is available at https://www.contrast-connect.com/blog-post/mri-contrast-reaction-management-documentation-protocol-explained

The new guide incorporates updated consensus recommendations from the American College of Radiology and the American Academy of Allergy, Asthma & Immunology, particularly emphasizing a departure from routine premedication for mild immediate reactions and prioritizing accurate electronic health record documentation of inciting agents. This evidence-based approach responds to evolving clinical data, including a 2025 consensus statement jointly issued by the American College of Radiology (ACR) and the American Academy of Allergy, Asthma & Immunology (AAAAI) that challenges prior premedication protocols and highlights the importance of identifying specific contrast agents to optimize future imaging decisions.

Clinical datasets from the ACR and the European Society of Urogenital Radiology (ESUR) indicate that the most severe acute reactions to iodinated contrast occur within 30 minutes of injection and require rapid recognition and standardized treatment protocols. Delays in administering epinephrine during anaphylaxis increase morbidity risks, yet inconsistent documentation has historically led to unnecessary premedication or delayed management. ContrastConnect's guide addresses these safety factors by outlining standardized workflows so that radiologists and specialized staff can intervene with precision.

Thorough documentation of the specific agent and symptom profile is now a critical expert recommendation. Rather than using generic labels like "contrast allergy," the guide outlines how to record precise details in the EHR to inform future imaging and reduce unnecessary prophylaxis. This practice aligns with the foundational recommendations of the ACR consensus statement, which positions accurate data as the key to minimizing repeat reactions.

The guide introduces a stratified premedication strategy based on reaction severity. Mild reactions no longer warrant routine premedication, while moderate reactions call for shared decision-making. For severe reactions, premedication is recommended only when alternative imaging is unfeasible. Furthermore, directly switching contrast agents—when the inciting agent is known—has proven more effective at reducing breakthrough reactions than premedication alone.

Anaphylaxis recognition and epinephrine-first management remain the foundation of any effective safety protocol. All imaging centers must be prepared with trained clinical staff and appropriate emergency supplies. The guide integrates these preparedness standards with documentation best practices, offering imaging networks a unified framework for managing adverse events while maintaining operational throughput.

"Our team supervises over 55,000 contrast exams monthly and manages 5-10 contrast reactions daily, bringing unmatched clinical experience," said a spokesperson for ContrastConnect. "Facilities partnering with us benefit from audit-ready documentation and the ability to extend coverage without adding on-site radiologists."

By standardizing reaction management and reducing care variation, this guide helps imaging groups implement evidence-based protocols across multiple facilities. Specialized teams are encouraged to integrate these recommendations into institutional workflows to enhance patient safety and procedural consistency.

For more details, visit https://www.contrast-connect.com/

Contact Info:
Name: Dor Shoshan
Email: Send Email
Organization: ContrastConnect
Address: Las vegas, Las Vegas, NV 89109, United States
Website: https://www.contrast-connect.com/

Source: PressCable

Release ID: 89183496

If there are any errors, inconsistencies, or queries arising from the content contained within this press release that require attention or if you need assistance with a press release takedown, we kindly request that you inform us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our reliable team will be available to promptly respond within 8 hours, taking proactive measures to rectify any identified issues or providing guidance on the removal process. Ensuring accurate and dependable information is our top priority.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  203.69
-6.42 (-3.06%)
AAPL  267.25
+2.67 (1.01%)
AMD  196.15
-4.00 (-2.00%)
BAC  51.03
-2.03 (-3.82%)
GOOG  314.08
-0.82 (-0.26%)
META  643.20
-12.46 (-1.90%)
MSFT  386.74
-10.49 (-2.64%)
NVDA  190.88
+1.06 (0.56%)
ORCL  139.12
-8.96 (-6.05%)
TSLA  397.05
-14.77 (-3.59%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.